Skip to content

Ernexa Therapeutics

3 viewers · 30d

Total raised

$7.2M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $7.2M
ROUNDS
1
INVESTORS
15
FOUNDED
N/A
HQ
Cambridge, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
3

AI overview

Updated

Ernexa Therapeutics Inc. is a biotechnology company focused on developing cell therapy solutions for advanced cancer and autoimmune diseases. They use induced pluripotent stem cells (iPSCs) to create induced mesenchymal stem cells (iMSCs) with unique targeting capabilities, enabling the creation of scalable, off-the-shelf therapies. This method eliminates the need for patient-specific solutions.

What sets it apart

Scalable iPSC-derived iMSC therapies

Funding history

1 round
Equity+2Mar 31, 2025
Form D
+$7.2M$7.2M total

Latest SEC filings

via EDGAR · CIK 0000748592
Form D · Mar 31, 2025View on EDGAR

Products

1 tracked

ERNA-101

Cell Therapy

ERNA-101 is a cell therapy product in development for the treatment of ovarian cancer. It leverages the natural tumor-homing abilities of iMSCs to deliver pro-inflammatory cytokines like IL-7 and IL-15 directly to the tumor microenvironment, enhancing the immune system's ability to target and destroy cancer cells.

  • iMSC-based cell therapy
  • Tumor-homing capabilities
  • Targeted delivery of pro-inflammatory cytokines
  • Enhanced immune response against cancer cells

Links

WebsiteLinkedInSEC EDGAR filings